RMI was created in March 2012. The investor of RMI is RUSNANO, the nanotechnology investment, research and development arm of the Russian Government. The main objectives of RMI are:
Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.